|
|
|
Insider
Information: |
Aselage Steve |
Relationship: |
Director |
City: |
Fremont |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
293,421 |
|
Indirect Shares
|
19,500 |
|
|
Direct
Value |
$6,843,889 |
|
|
Indirect Value
|
$130,455 |
|
|
Total
Shares |
312,921 |
|
|
Total
Value |
$6,974,344 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
4
|
5
|
Stock
price went up :
|
0
|
3
|
Stock
price went down : |
4
|
2
|
|
|
|
Gain/Loss Ratio : |
-4.0
|
1.5
|
Percentage
Gain/Loss : |
-31.1%
|
62.9%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Cti Biopharma Corporation |
CTIC |
EVP, Global Commercial... |
2005-06-30 |
24,133 |
2004-08-03 |
0 |
Premium* |
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Business Of... |
2012-07-02 |
59,030 |
2006-04-28 |
0 |
Premium* |
|
Travere Therapeutics, Inc |
TVTX |
Director |
2022-05-11 |
146,919 |
2021-11-05 |
19,500 |
Premium* |
|
Acer Therapeutics Inc |
ACER |
Director |
2023-11-17 |
0 |
2017-09-19 |
0 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2023-06-13 |
63,339 |
2019-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
169 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 6 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2016-11-21 |
4 |
S |
$21.00 |
$105,000 |
D/D |
(5,000) |
243,756 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-11-05 |
4 |
AS |
$21.26 |
$53,150 |
D/D |
(2,500) |
233,732 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2016-11-22 |
4 |
S |
$21.30 |
$68,160 |
D/D |
(3,200) |
240,556 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2019-02-11 |
4 |
AS |
$21.38 |
$22,770 |
D/D |
(1,065) |
258,707 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-03-04 |
4 |
S |
$21.50 |
$107,500 |
D/D |
(5,000) |
50,361 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2019-02-12 |
4 |
AS |
$21.50 |
$22,898 |
D/D |
(1,065) |
257,642 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2018-12-21 |
4 |
AS |
$21.69 |
$134,829 |
D/D |
(6,188) |
259,772 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2022-05-11 |
4 |
S |
$21.92 |
$56,457 |
D/D |
(2,575) |
146,919 |
0 |
% |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-03-05 |
4 |
S |
$21.95 |
$140,831 |
D/D |
(6,416) |
43,945 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2018-12-20 |
4 |
AS |
$21.97 |
$135,958 |
D/D |
(6,188) |
265,960 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-09-08 |
4 |
S |
$22.00 |
$770,000 |
D/D |
(35,000) |
37,587 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-03-08 |
4 |
S |
$22.11 |
$532,526 |
D/D |
(24,090) |
19,855 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
|
2007-09-14 |
4 |
S |
$22.40 |
$224,000 |
D/D |
(10,000) |
4,895 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-11-06 |
4 |
AS |
$23.00 |
$474,375 |
D/D |
(20,625) |
213,107 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-12-02 |
4 |
S |
$23.43 |
$184,849 |
D/D |
(7,891) |
202,216 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2018-11-14 |
4 |
AS |
$23.63 |
$131,735 |
D/D |
(5,550) |
258,833 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2018-12-07 |
4 |
S |
$24.04 |
$240 |
D/D |
(10) |
251,523 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
|
2018-11-15 |
4 |
AS |
$24.21 |
$134,969 |
D/D |
(5,550) |
253,283 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
|
2007-10-01 |
4 |
AS |
$24.90 |
$125,471 |
D/D |
(5,000) |
4,895 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-11-17 |
4 |
S |
$25.75 |
$206,000 |
D/D |
(8,000) |
29,881 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-11-17 |
4 |
S |
$25.80 |
$12,900 |
D/D |
(500) |
61,256 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
|
2010-11-18 |
4 |
S |
$25.87 |
$811,546 |
D/D |
(31,375) |
29,881 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2020-12-15 |
4 |
S |
$26.02 |
$144,385 |
D/D |
(5,549) |
196,667 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2021-04-16 |
4 |
AS |
$26.23 |
$262,300 |
D/D |
(10,000) |
188,940 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Director |
|
2021-10-07 |
4 |
AS |
$26.23 |
$1,574,760 |
D/D |
(60,000) |
189,794 |
0 |
% |
|
169 Records found
|
|
Page 6 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|